PCV39 ECONOMIC IMPACT OF SWITCHING FROM ENTERIC COATED ASPIRIN TABLETS TO LIQUID FILLED CAPSULES WITH A NOVEL PHARMACEUTICAL LIPID-ASPIRIN COMPLEX IN PATIENTS SURVIVING AN ACUTE CARDIOVASCULAR EVENT

Abstract

A new, pharmaceutical lipid-aspirin complex (PL-ASA) formulation has been specifically developed to reduce the risk of aspirin-induced gastric injury. In clinical studies PL-ASA liquid-filled capsules were shown to have significantly higher rates of complete aspirin response compared with the current standard of care (enteric coated aspirin tablets [EC-ASA]). Aspirin response has been linked to avoidance of ischemic events such as myocardial infarction MI) or stroke. In the current analysis we sought to determine the economic impact of switching patients from EC-ASA to PL-ASA for the first year following an index MI or stroke.